(Reuters) – European health regulator said on Thursday it was assessing a marketing authorisation application for GSK-Vir Biotechnology’s monoclonal antibody treatment for COVID-19 and could give its opinion within two months.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shinjini Ganguli)
